Bedaquiline resistance: a predictable consequence of a game-changing drug?
ASM Case Reports · 07.07.2026 · 2 (4)
DOI: 10.1128/asmcr.00228-25 ↗Kurz gefasst
Kommentar in der Zeitschrift ASM Case Reports, erschienen am 07.07.2026. Verfasst von Ronald Lubelchek. Beteiligte Einrichtung: Cook County Department of Public Health, Forest Park, Illinois, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bedaquiline’s (BDQ) incorporation into the recommended treatment for drug-resistant tuberculosis (DR-TB) has ushered in a new era of highly effective, shorter course, all-oral regimens. Unfortunately, as the uptake of BDQ-based regimens has increased, so has the emergence of BDQ resistance. In a recent ASM Case Reports article, M. Richard-Greenblatt, R. Bagga, C. Duncan, M. J. Billick, et al. (ASM Case Rep 2:e00126-25, 2025, https://doi.org/10.1128/asmcr.00126-25 ) reported on a patient with treatment-emergent extensively drug-resistant (XDR) TB, whose isolate harbored a novel loss-of-function pepQ mutation, with resulting BDQ resistance. This commentary briefly highlights the benefits of BDQ-based DR-TB therapy, while also reviewing data related to the growing challenge posed by BDQ resistance.
Autor:innen und Institutionen
- Cook County Department of Public Health, Forest Park, Illinois, USA.
- Division of Infectious Diseases, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, USA.
ORCID-Profile: Ronald Lubelchek
Zitieren
APA
Lubelchek, R. (2026). Bedaquiline resistance: a predictable consequence of a game-changing drug?. ASM Case Reports, 2(4). https://doi.org/10.1128/asmcr.00228-25
Vancouver
Lubelchek R. Bedaquiline resistance: a predictable consequence of a game-changing drug?. ASM Case Reports. 2026;2(4). doi:10.1128/asmcr.00228-25
BibTeX
@article{Lubelchek2026,
author = {Lubelchek, Ronald},
title = {Bedaquiline resistance: a predictable consequence of a game-changing drug?},
journal = {ASM Case Reports},
year = {2026},
volume = {2},
number = {4},
doi = {10.1128/asmcr.00228-25}
}
EUVIMED